Venture Life (#VLG) – trading “continued momentum… well positioned to deliver significant organic growth over the coming years”

Venture Life (#VLG) – acquisition of FemiClear and CUROXEN for an initial $23m and up to a further $5m

Venture Life – emphasises trading “confidence”, but now take profits on this winning share tip?

Venture Life Group (VLG) has announced completion of the sale of its contract development and manufacturing operations and some, non-core, products and “confidence that full year financial performance is on-course to be in line with market expectations”. How does this latest news compare to a share price at 58.5p compared to a 39.5p offer price tip just in November?

Venture Life (#VLG) – completes a non-core products and contract development and manufacturing business sale, “full year financial performance is on-course”

Venture Life – now a significant corporate move from this winning share tip

Venture Life Group (VLG) has announced an agreement to sell its contract development and manufacturing business and some ‘non-core’ products and associated commercial agreements to portfolio company of investment firm The Riverside Company, BioDue, for €62 million on a cash-free debt-free basis. With Venture Life’s market cap having been £57.6 million at a 45p share price, just how good is this news?

Venture Life (#VLG) – agreement for sale of contract development and manufacturing business and certain “non-core” products for €62m

Venture Life – 2024 “challenging” but a positive growth outlook, Buy...

‘Self-care’ products group Venture Life (VLG) has announced a trading update for its year ended 31st December 2024 and that it is “extremely positive for the outlook for growth in both our revenues and profitability in 2025”. So good news from a 34p share price?

Venture Life Group – growth value: BUY

Following results and acquisition announcements in the last couple of months, shares in consumer self-care products developer and manufacturer Venture Life Group (VLG) have fallen back from approaching 50p to below 40p. However, the following is why we consider they have the potential to exceed 50p again.

Venture Life (#VLG) – argues in line with expectations, but H2 weighting “as is customary… particularly in the case of our international partners”

Venture Life (#VLG) – notes 2023 progress “in line with management expectations”

Venture Life – half-year trading update, how confident to be for second half weighting?

‘Self-care’ products group Venture Life (VLG) commences a trading update with that it “expects to report revenues for the six months ended 30 June 2022 of £18.9 million, a growth of 36% over the same period previous year” and adds “order book remains strong and is ahead of the same period last year”. So what of a current share price response up more than 9% at 35p?

Venture Life (#VLG) – reiterates guidance for 2021 but results delay due to auditor “resourcing issues”

Venture Life Group – a trading statement it’s “pleased to provide”. Should it be?...

‘Self-care’ products group Venture Life (VLG) has made a trading statement and the shares have currently responded to around 50p, 34% higher, on the back of it. Is this justified?...

Venture Life (#VLG) – updates on “difficult” 2021, current order book “significantly ahead” of last year

Venture Life (#VLG) – new China partner Samarkand (#SMK) after prior partner “absence of any improvement” in H2

Venture Life – “many reasons to be optimistic” and “pleased with how the company is positioned”. Really?...

Describing itself as “a leader in developing, manufacturing and commercialising products for the self-care market”, a “Trading Update & Board Changes” announcement from Venture Life Group (VLG) includes “the directors see many reasons to be optimistic and are pleased with how the company is positioned… The company is profitable, cash generative, with a healthy cash balance… order book ahead of where it was at the same time last year (on a like for like basis)”. So why then are the shares, at circa 35p, 27% lower on the back of it?...

Venture Life (#VLG) – emphasises “remarkable” H1, “remain confident” & “continue to explore additive M&A opportunities”

Venture Life (#VLG) – H1 revenue +6%, H2 increase “evidenced by the group's order book”

Venture Life (#VLG) – completes £18.75m placing & acquisition of Dentyl

Venture Life (#VLG) – proposed acquisition of Dentyl, £18.75m placing at 40p